BC Week In Review | Aug 10, 2015
Clinical News

DP-b99: Phase II final data

Final data from a double-blind, European Phase II trial in 10 patients with acute, high-risk pancreatitis showed that twice-daily IV DP-b99 for 2 days was well tolerated. Additionally, a non-pre-specified analysis of inflammatory markers showed...
BC Week In Review | Dec 9, 2013
Clinical News

DP-b99: Phase II started

D-Pharm began a double-blind, placebo-controlled, European Phase II trial to evaluate twice-daily IV DP-b99 for 2 days in 30 patients with high-risk acute pancreatitis. Last year, the company discontinued development of the compound to treat...
BC Week In Review | Oct 21, 2013
Clinical News

DP-b99: Phase II start

This quarter, D-Pharm will begin a double-blind, placebo-controlled Phase II trial to evaluate DP-b99 in patients with acute pancreatitis. Last year, the company discontinued development of the compound to treat ischemic stroke due to lack...
BC Week In Review | May 28, 2012
Company News

D-Pharm, Thrombotech deal

D-Pharm will merge with stroke company Thrombotech in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In February, D-Pharm said it was in negotiations...
BioCentury | May 28, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Furiex Pharmaceuticals Inc. (NASDAQ:FURX) gained $3.34 (21%) to $19.10 last week after EMA accepted for review an MAA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for alogliptin to treat Type II diabetes. The acceptance...
BC Extra | May 25, 2012
Company News

D-Pharm, Thrombotech to merge

D-Pharm Ltd. (Tel Aviv:DPRM) will merge with stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In...
BC Week In Review | Mar 5, 2012
Clinical News

DP-b99: Development discontinued

D-Pharm discontinued development of DP-b99 to treat stroke after an interim analysis of the double-blind, placebo-controlled, international Phase III MACSI trial showed that the compound met undisclosed criteria for futility. No safety concerns were identified....
BC Week In Review | Mar 5, 2012
Company News

D-Pharm, Thrombotech deal

D-Pharm said it is in negotiations to acquire stroke company Thrombotech in a stock deal after discontinuing development of its own stroke therapy in January due to lack of efficacy. On Jan. 24, D-Pharm plummeted...
BC Extra | Feb 28, 2012
Company News

D-Pharm seeking Thrombotech acquisition after Phase III halt

D-Pharm Ltd. (Tel Aviv:DPRM) said it is in negotiations to acquire stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal after discontinuing development of its own stroke therapy last month due to lack...
BioCentury | Jan 9, 2012
Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders....
Items per page:
1 - 10 of 41